Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 11;57(2):2002127.
doi: 10.1183/13993003.02127-2020. Print 2021 Feb.

Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort

Olaf Holz  1   2   3 , Benjamin Waschki  4   5   6   3 , Henrik Watz  6   7 , Anne Kirsten  6   7 , Mustafa Abdo  5   6 , Frauke Pedersen  6   7 , Markus Weckmann  6   8 , Oliver Fuchs  9   10 , Anna-Maria Dittrich  2   11 , Gesine Hansen  2   11 , Matthias V Kopp  6   8 , Erika von Mutius  10   12 , Klaus F Rabe  5   6 , Jens M Hohlfeld  1   2   13   14 , Thomas Bahmer  5   15   14 ; ALLIANCE Study Group
Affiliations

Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort

Olaf Holz et al. Eur Respir J. .

Abstract

Despite recent publications, we are not close to finding a clinically valuable breath VOC biomarker for asthma or asthma phenotypes https://bit.ly/3heTgtK

Trial registration: ClinicalTrials.gov NCT02419274.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: O. Holz has nothing to disclose. Conflict of interest: B. Waschki has nothing to disclose. Conflict of interest: H. Watz has nothing to disclose. Conflict of interest: A. Kirsten has nothing to disclose. Conflict of interest: M. Abdo has nothing to disclose. Conflict of interest: F. Pedersen has nothing to disclose. Conflict of interest: M. Weckmann has nothing to disclose. Conflict of interest: O. Fuchs has nothing to disclose. Conflict of interest: A-M. Dittrich has nothing to disclose. Conflict of interest: G. Hansen reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study. Conflict of interest: M.V. Kopp reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; personal fees for lectures and consultancy from ALK-Abello, Allergopharma, Chiesi, Meda, Novartis Pharma, Vertex, Abbvie and Infectopharm, grants from Allergopharma and Vertex, outside the submitted work. Conflict of interest: E. von Mutius reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; authorship fees from Springer-Verlag GmbH, Georg Thieme Verlag and Elsevier Ltd, personal fees for consultancy from HiPP GmbH & Co. KG, OM Pharma SA and Peptinnovate Ltd, personal fees for lectures from Boehringer Ingelheim International GmbH, outside the submitted work; and has a patent LU101064, “Barn dust extract for the prevention and treatment of diseases” pending, a patent EP2361632, “Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders” with royalties paid to ProtectImmun GmbH, a patent number EP 1411977, “Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases” licensed to ProtectImmun GmbH, a patent EP1637147, “Stable dust extract for allergy protection” licensed to ProtectImmun GmbH, and a patent EP 1964570, “Pharmaceutical compound to protect against allergies and inflammatory diseases” licensed to ProtectImmun GmbH. Conflict of interest: K.F. Rabe reports grants and personal fees from Boehringer Ingelheim and AstraZeneca, personal fees from Novartis, Sanofi, Regeneron, Roche and Chiesi Pharmaceuticals outside the submitted work. Conflict of interest: J.M. Hohlfeld reports grants from German Ministry for Education and Research (BMBF; grant DZL 2016-2020/82DZL002A2), during the conduct of the study; personal fees for consultancy from Boehringer Ingelheim and Merck & Co., Inc., personal fees for lectures from Novartis and HAL, grants from AstraZeneca AB, Novartis, Janssen Pharmaceutica NV, ALK, Boehringer Ingelheim, LETI, GlaxoSmithKline, Sanofi-Aventis, Astellas Pharma and Allergopharma, outside the submitted work. Conflict of interest: T. Bahmer reports grants from BMBF (unrestricted research grant for the German Center for Lung Research, DZL), during the conduct of the study; personal fees lectures and consultancy, and compensation of travel expenses from AstraZeneca, GlaxoSmithKline, Novartis and Roche, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
a) Patient demographics according to asthma phenotypes. Data are presented as median (interquartile range). Statistics: Kruskal–Wallis ANOVA. ICS: inhaled corticosteroids; OCS: oral corticosteroids; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity; sRtot: specific total airway resistance; R5Hz: resistance at 5 Hz; FDRabs: frequency dependence of resistance (resistance at 5 Hz minus resistance at 20 Hz). #: omalizumab or mepolizumab; : missing values. b) Gas chromatography/mass spectrometry chromatogram of one representative patient with inserts and arrows indicating the retention time (RT) for propanol-1, hexane, 2-hexanone and nonanal [3]. The black line indicates the total ion content (TIC), the insert coloured plots show specific masses of the respective volatile organic compounds (VOCs). c–e) Correlation between VOCs and sputum neutrophils (%). All patients and subgroup correlations not significant (unadjusted p-value >0.05). f) Correlation between hexane and sputum eosinophils (%). All patients and subgroup correlations not significant (unadjusted p-value >0.05), except for smokers (r=−0.45, unadjusted p-value 0.02, adjusted p-value 0.48). Selection of VOCs based on published data [3]. As shown in (b), 2-hexanone was not detectable in our samples. g) Histograms of unadjusted p-values for the correlation between all detected VOCs and sputum neutrophils and eosinophils (%), exhaled nitric oxide fraction (FENO) and blood eosinophils (%). a.u.: arbitrary units.
See this image and copyright information in PMC

References

    1. Azim A, Barber C, Dennison P, et al. . Exhaled volatile organic compounds in adult asthma: a systematic review. Eur Respir J 2019; 54: 1900056. doi:10.1183/13993003.00056-2019 - DOI - PubMed
    1. de Vries R, Dagelet YWF, Spoor P, et al. . Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label. Eur Respir J 2018; 51: 1701817. doi:10.1183/13993003.01817-2017 - DOI - PubMed
    1. Schleich FN, Zanella D, Stefanuto P-H, et al. . Exhaled volatile organic compounds are able to discriminate between neutrophilic and eosinophilic asthma. Am J Respir Crit Care Med 2019; 200: 444–453. doi:10.1164/rccm.201811-2210OC - DOI - PubMed
    1. Sterk PJ Modern inflammatory phenotyping of asthma. Breathomics is here to stay. Am J Respir Crit Care Med 2019; 200: 405–406. doi:10.1164/rccm.201904-0733ED - DOI - PMC - PubMed
    1. Fowler SJ, Sterk PJ. Breath biomarkers in asthma: we're getting answers, but what are the important questions? Eur Respir J 2019; 54: 1901411. doi:10.1183/13993003.01411-2019 - DOI - PubMed

Publication types

Associated data